Trials / Withdrawn
WithdrawnNCT04231526
Pembrolizumab in Early Stage Colon Cancer
A Window of Opportunity Study of Pembrolizumab in Colon Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will gather information on the safety and effectiveness of pembrolizumab, an immunotherapy drug. The purpose of this study is to target early stage colon cancer before it has developed resistance to immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days) |
| PROCEDURE | Surgery | Standard of care surgery |
Timeline
- Start date
- 2020-05-20
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-01-18
- Last updated
- 2024-07-31
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04231526. Inclusion in this directory is not an endorsement.